Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium

ObjectiveThe impact of angiogenesis on long-term survival of high-grade serous ovarian cancer (HGSOC) patients remains unclear. This study investigated whether angiogenic markers correlated with 5-year progression-free survival (PFS) in a large cohort of matched advanced HGSOC tissue samples.MethodsTumor samples from 124 primary HGSOC patients were retrospectively collected within the Tumor Bank Ovarian Cancer (http://www.toc-network.de). All patients were in advanced stages (FIGO stage III-IV). No patient had received anti-angiogenesis therapy. The cohort contains 62 long-term survivors and 62 controls matched by age and post-surgical tumor residuals. Long-term survivors were defined as patients with no relapse within 5years after the end of first-line chemotherapy. Controls were patients who suffered from first relapse within 6-36months after primary treatment. Samples were assessed for immunohistochemical expression of vascular endothelial growth factor (VEGF) A and VEGF receptor 2 (VEGFR2). Expression profiles of VEGFA and VEGFR2 were compared between the two groups.ResultsSignificant correlation between VEGFA and VEGFR2 expression was observed (p<0.0001, Spearman coefficient 0.347). A high expression of VEGFR2 (VEGFR2(high)) was found more frequently in long-term survivors (77.4%, 48/62) than in controls (51.6%, 30/62, p=0.001), independent of FIGO stage and VEGFA expression in multivariate analysis (p=0.005). Also, VEGFR2(high) was found the most frequently in women with PFS10years (p=0.001) among all 124 patients. However, no significant association was detected between VEGFA expression and 5-year PFS (p=0.075).ConclusionsVEGFR2 overexpression significantly correlated with long-term PFS in HGSOC patients, independent of age, FIGO stage, tumor residual and VEGFA expression.